JP2003530432A5 - - Google Patents

Download PDF

Info

Publication number
JP2003530432A5
JP2003530432A5 JP2001576010A JP2001576010A JP2003530432A5 JP 2003530432 A5 JP2003530432 A5 JP 2003530432A5 JP 2001576010 A JP2001576010 A JP 2001576010A JP 2001576010 A JP2001576010 A JP 2001576010A JP 2003530432 A5 JP2003530432 A5 JP 2003530432A5
Authority
JP
Japan
Prior art keywords
kit
group
agent
derivative
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001576010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530432A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/012484 external-priority patent/WO2001078709A2/en
Publication of JP2003530432A publication Critical patent/JP2003530432A/ja
Publication of JP2003530432A5 publication Critical patent/JP2003530432A5/ja
Pending legal-status Critical Current

Links

JP2001576010A 2000-04-12 2001-04-12 神経変性疾患の治療 Pending JP2003530432A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US19649700P 2000-04-12 2000-04-12
US60/196,497 2000-04-12
US21422100P 2000-06-23 2000-06-23
US60/214,221 2000-06-23
US24889000P 2000-11-15 2000-11-15
US60/248,890 2000-11-15
PCT/US2001/012484 WO2001078709A2 (en) 2000-04-12 2001-04-12 Treatment of neurodegenerative disease

Publications (2)

Publication Number Publication Date
JP2003530432A JP2003530432A (ja) 2003-10-14
JP2003530432A5 true JP2003530432A5 (enExample) 2008-06-05

Family

ID=27393612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001576010A Pending JP2003530432A (ja) 2000-04-12 2001-04-12 神経変性疾患の治療

Country Status (6)

Country Link
US (1) US20030060487A1 (enExample)
EP (1) EP1328261A2 (enExample)
JP (1) JP2003530432A (enExample)
AU (1) AU2001253597A1 (enExample)
CA (1) CA2404858A1 (enExample)
WO (1) WO2001078709A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148101A1 (en) * 1999-01-23 2005-07-07 Bamdad Cynthia C. Interaction of colloid-immobilized species with species on non-colloidal structures
JP4585170B2 (ja) 2000-10-03 2010-11-24 ミナーヴァ・バイオテクノロジーズ・コーポレーション 流動の中断に基づく相互作用の電子検出および相互作用の検出
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
EP1423537A4 (en) * 2001-08-07 2006-11-29 Univ Delaware COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HUNTINGTON'S DISEASE
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
FR2828693B1 (fr) † 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
US20060280730A1 (en) * 2001-10-12 2006-12-14 Cedars-Sinai Medical Center Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels
AU2003300371A1 (en) 2002-12-20 2004-07-22 Minerva Biotechnologies Corporation Optical devices and methods involving nanoparticles
ES2272911T3 (es) * 2003-04-25 2007-05-01 Neurofit Sas Uso de derivados de fenotiazina piperazina en la fabricacion de un medicamento con efectos neuroprotector y/o neurotroficos sobre cns y/o pns.
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
RU2416603C9 (ru) 2005-10-25 2012-06-20 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
WO2007097707A1 (en) * 2006-02-24 2007-08-30 Axelar Ab Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
WO2009005469A2 (en) * 2007-07-03 2009-01-08 David Erlinge The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
KR20120104570A (ko) 2009-12-11 2012-09-21 시오노기세야쿠 가부시키가이샤 옥사진 유도체
KR101351181B1 (ko) * 2010-05-11 2014-01-14 가천대학교 산학협력단 단핵식세포계 세포 내에서 ａｇｅ-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법
US20120101167A1 (en) 2010-10-25 2012-04-26 Langham Maurice E Treatment of ocular and cerebral ischemia
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
EP2634186A4 (en) 2010-10-29 2014-03-26 Shionogi & Co naphthyridine
EP2703399A4 (en) 2011-04-26 2014-10-15 Shionogi & Co OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤
CN102381991A (zh) * 2011-10-22 2012-03-21 杭州福斯特药业有限公司 一种章胺盐酸盐的合成方法
EP2830620A4 (en) * 2012-03-26 2015-12-09 Univ Columbia 4-AMINOPYRIDINE AS A THERAPEUTIC AGENT FOR SPINAL MUSCLE ATROPHY
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
US11648212B2 (en) * 2016-02-03 2023-05-16 Intelgenx Corp. Loxapine film oral dosage form
KR20190017795A (ko) 2016-05-13 2019-02-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 아드레날린 수용체 조절 화합물 및 이의 사용 방법
WO2022087460A1 (en) * 2020-10-22 2022-04-28 Icahn School Of Medicine At Mount Sinai Methods for identifying and targeting the molecular subtypes of alzheimer's disease

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) * 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) * 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
ES2074441T3 (es) * 1987-10-05 1995-09-16 Yamanouchi Pharma Co Ltd Compuestos espiro heterociclicos y su preparacion.
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE4023369A1 (de) * 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5338663A (en) * 1990-08-24 1994-08-16 President And Fellows Of Harvard College Method of identifying inhibitors of β-protein esterase activity
JPH04167172A (ja) * 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5238942A (en) * 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5962463A (en) * 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
IL112567A (en) * 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AU3641597A (en) * 1996-06-21 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions comprising r-ibuprofen
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
CN1076022C (zh) * 1996-08-29 2001-12-12 武田药品工业株式会社 作为钠通道调节剂的环醚化合物
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
IL130162A (en) * 1996-12-12 2008-03-20 Yissum Res Dev Co Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
AU5727798A (en) * 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US6130221A (en) * 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
IL132169A0 (en) * 1997-04-28 2001-03-19 Univ British Columbia Method and composition for modulating amyloidosis
US6514686B2 (en) * 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
US6586475B1 (en) * 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
EP1132372A3 (en) * 2000-03-06 2003-11-19 Solvias AG Bicyclic 1,3-aminoalcohols, d8-metal complexes and hydrogenation processes
JP4585170B2 (ja) * 2000-10-03 2010-11-24 ミナーヴァ・バイオテクノロジーズ・コーポレーション 流動の中断に基づく相互作用の電子検出および相互作用の検出
WO2002061129A2 (en) * 2000-11-15 2002-08-08 Minerva Biotechnologies Corporation Oligonucleotide identifiers
US20020156112A1 (en) * 2000-11-15 2002-10-24 Bamdad R. Shoshana Endostatin-like angiogenesis inhibition

Similar Documents

Publication Publication Date Title
JP2003530432A5 (enExample)
US10676472B2 (en) Crystal forms of glutaminase inhibitors
JP4212149B2 (ja) 医薬
JP2009536620A5 (enExample)
JP2010509356A5 (enExample)
JP2005519908A5 (enExample)
JP2013530964A5 (enExample)
JP2007519649A5 (enExample)
JP2009515887A5 (enExample)
EP1988898A2 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
WO2007146073A2 (en) Method for enhancing cognitive function
JP2019511204A (ja) コパンリシブバイオマーカー
JP2009541387A5 (enExample)
JP2007538031A5 (enExample)
CN111727044A (zh) 用于治疗癌症或炎性疾病的杂二环羧酸
JP2005500370A5 (enExample)
JP2003513066A5 (enExample)
CN107207510A (zh) 联合疗法
TW201927298A (zh) 賽佩普斯特（Ｓｅｐｅｔａｐｒｏｓｔ）及Ｒｈｏ激酶抑制劑之組合醫藥
JP4246997B2 (ja) 糖尿病由来虚血性心疾患の治療及び／または予防剤
JP7493939B2 (ja) 関節リウマチの治療用組成物および治療方法
JPH02138214A (ja) 不安を治療する方法
JP2006510632A5 (enExample)
AU2008257322B2 (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to Parkinson's disease
AU2012258339A1 (en) New combination between 4-{3-[Cis-Hexahydrocyclopenta[c]Pyrrol-2(1H)-yl]Propoxy}Benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it